Mucosa-Associated Lymphoid Tissue Lymphomas (MALTomas)

Mucosa-Associated Lymphoid Tissue Lymphomas (MALTomas)

No Results

No Results


Mucosa-associated lymphoid tissue (MALT) is scattered along mucosal linings in the human body [1, 2, 3] and constitutes the most extensive component of human lymphoid tissue. These surfaces protect the body from an enormous quantity and variety of antigens. The tonsils, the Peyer patches within the small intestine, and the vermiform appendix are examples of MALT.

The nomenclature incorporates location; therefore, MALT is understood to include gut-associated lymphoid tissue (GALT), bronchial/tracheal-associated lymphoid tissue (BALT), nose-associated lymphoid tissue (NALT), and vulvovaginal-associated lymphoid tissue (VALT). Additional MALT exists within the accessory organs of the digestive tract, predominantly the parotid gland.

Chronic inflammation of MALT from infective or autoimmune disorders can lead to the development of extranodal marginal zone B-cell lymphomas, or MALTomas. The stomach is the most common location of MALTomas, while frequent nongastric sites include the following [4] :

MALTomas at different sites may involve different genetic lesions and may possibly have different natural histories. [4]

Symptoms of MALTomas are nonspecific and are related to the organs involved. Most patients with MALTomas have no physical findings; lymphadenopathy is rare. Staging MALTomas can be challenging. Imaging studies are not helpful for visualizing normal MALT, but they may be useful in diagnosing and staging MALTomas. Endoscopy may be helpful. Bone marrow aspiration and biopsy findings can signal bone marrow involvement.

Treatment may include proton pump inhibitors (PPIs) and antibiotics for Helicobacter pylori infection, chemotherapy, radiotherapy, and, in some instances, surgical intervention.

For patient education resources, see the Blood and Lymphatic System Center, as well as Lymphoma.

MALT may consist of a collection of lymphoid cells, or it may include small solitary lymph nodes. Lymph nodes contain a light-staining region (germinal center) and a peripheral dark-staining region. The germinal center is key to the generation of a normal immune response. The location of MALT is key to its function. Stimulation of B cells leads to the production of immunoglobulin A (IgA) and immunoglobulin M (IgM) within the Peyer patches, preventing adherence of bacteria and viruses to the epithelium and thus blocking entry to the subepithelial layers of the intestine. [1, 2, 3, 5]

Mucosal epithelial surfaces contain M cells, specialized cells that are so named because they exhibit microfolds on their luminal surface and have a membranous appearance. The roles of the M cells include absorption, transport, processing, and presentation of antigens to subepithelial lymphoid cells. [6, 7] These subepithelial cells include CD4+ type 1 T helper cells (THCs) and immunoglobulin D (IgD)/IgM+ B cells; the latter are antigen-presenting cells (APCs) that function as memory cells interacting with type 1 THCs.

Under these M cells and in close proximity, B cells, CD4+ T cells, and APCs (including dendritic follicular cells [DFCs]) are found. [8] Together, this group of cells constitutes a “pocket” of M cells. Within this pocket, an area of follicles associated with the epithelium (follicle-associated epithelium) is observed. These follicles, having true germinal centers, are similar to the follicles of the spleen and lymph nodes.

The direct secretion of secretory IgA onto mucosal epithelia represents the major effector mechanism of MALT. Major accumulations of lymphoid tissue are found in the lamina propria of the intestine. M cells in the intestinal epithelium overlying Peyer patches allow transport of antigens to the lymphoid tissue beneath it.

DFCs activate some clones of type 1 THCs, although less potently than B cells do. Stimulation of CD28 on type 1 THCs by B7 costimulatory molecules results in the secretion of interleukin (IL)–2 and interferon gamma by type 1 THCs. Regulation of the immune response involves the suppression of type 2 THCs (involved in humoral immunity) by interferon gamma and the production of IL-10 by type 2 THCs, which inhibits type 1 THCs.

Tolerance to antigens results from the lack of a T-cell response. Often, this is attributable to failed involvement of B-cell costimulatory molecules or cytokines. Signaling requires more than just receptor stimulation.

The activity of the germinal centers in the follicle-associated epithelium is key to the immune response. The germinal center provides an area where a large number of cells important in the immune response congregate. Early on in the T-cell–dependent immune response, B cells known as founder cells concentrate in the germinal center, forming the dark zone, where rapid division of these cells occurs. [9, 10, 11, 12]

Selection of B cells for participation in the immune response occurs on the basis of their interaction with antigen-antibody complexes on the surface of DFCs. This involves a series of steps that result in expression of complexes of major histocompatibility complex II (MHC II) and peptides resulting from processed antigens. This begins a process of somatic hypermutation in the dark zone, which is followed by immunoglobulin class-switching and generation of memory cells and plasma cell precursors in the apical light zone of the germinal center.

The complex interplay among antigens, cells, and cytokines results in a very efficient immune response. The efficiency of MALT depends on adequate IgA function, which, in turn, depends on production and acquisition of a joining (J) chain. This chain, a glycoprotein produced by plasma cells, is important in the formation of IgA dimers and IgM pentamers and is key in permitting secretory IgA and IgM to function as the first line of defense in mucosal epithelium. In children with recurrent tonsillitis, B cells in tonsillar crypts do not produce the J chain.

Individuals with selective IgA deficiency are prone to infections along mucosal surfaces in the respiratory, gastrointestinal (GI), and genitourinary (GU) tracts. The capability of the mucosal barrier is weakened, and a second line of defense is activated. This consists of the participation and recruitment of large numbers of immune-competent cells, resulting in the onset of an inflammatory process that eradicates the antigen and restores functionality to the mucosa. If this process is constant and intense, it may result in a chronic inflammatory process. [13]

Malignancies that occur in MALT are called MALT lymphomas or MALTomas. MALTomas are extranodal manifestations of marginal-zone lymphomas. Most MALTomas are low-grade lesions, though a minority either manifest initially as intermediate-grade non-Hodgkin lymphoma (NHL) or evolve from the low-grade form. Most MALTomas occur in the stomach and in more than 90% of cases, MALT lymphoma is associated with H pylori infection. [14]

Several cytogenetic abnormalities have been identified, the most common being trisomy 3 or t(11;18). The specific gene abnormalities responsible for the pathogenesis of MALTomas have not yet been identified. Mutations commonly identified in NHLs are not commonly present in MALTomas, though both BCL2 and TP53 have been reported. [15]

Although the cause of MALTomas and most other tumors is still unknown, accumulated evidence indicates a strong association between autoimmune diseases and MALTomas. Continued massive antigen stimulation is postulated to represent a critical step in the development and progression of MALTomas.

MALTomas of the salivary glands are often associated with Sjögren syndrome. [16] MALTomas of the thyroid are associated with Hashimoto thyroiditis. Crohn disease or celiac disease may be involved in the genesis of intestinal MALTomas.

In contrast to the weaker etiologic associations, a clear causal association between H pylori infection and gastric MALTomas has been definitively established. H pylori gastritis is common in individuals who develop gastric lymphomas.

Non-Hodgkin lymphomas (NHLs) account for 2-3% of all malignancies, and MALTomas account for approximately 5% of NHLs diagnosed annually. NHL represents only 4% of non–skin cancer malignancies. Although extensive studies have not been performed, no particular ethnic group or geographic area shows a strong predilection for MALTomas.

The peak incidence of MALTomas is during the seventh and eighth decades of life. However, MALTomas have been noted in children, adolescents, and young adults. No sex-related differences in MALT distribution are known, but males usually have a more extensive distribution of lymphoid tissue; some studies suggest that MALTomas are slightly more common in females than in males. No significant racial differences are known; some studies suggest that MALTomas are slightly more common in whites than in blacks.

Morbidity and mortality occur when neoplastic transformation into a MALToma develops. Most MALTomas are responsive to available treatment modalities, including radiation and chemotherapy. In addition, H pylori–associated tumors may respond to antibiotics. [17]

The prognosis depends on the grade of the tumor, with long-term survival possible for patients with low-grade tumors. However, achieving a cure is more difficult in patients with MALTomas in advanced stages.

Generally, low-grade MALTomas are indolent neoplasms with a fairly good prognosis. Although the intermediate-grade, diffuse, large B-cell MALTomas are more aggressive malignancies, the cure rate may be as high as 90% for stage IE disease and is approximately 30-40% for extensive stage IIIE or IVE disease. These outcomes are similar to those of non-MALT intermediate-grade NHLs.

Gastric MALTomas have a stage-dependent prognosis. The survival rate for stage IE disease is 93% at 5 years and 58% at 10 years. [18] Long-term responses to anti–H pylori treatment alone have been reported; MALTomas that are not eradicated by treatment of H pylori infection are incurable but are associated with a prolonged course. A retrospective study from China suggested that the t(11;18)(q21;q21) translocation may be an important prognostic factor for patients with gastric MALTomas. [19]

The most common morbidities associated with GI MALTomas include abdominal pain, GI bleeding, and GI obstruction. Gastric or intestinal perforation is rare.

Nongastrointestinal MALTomas are most common in the head and neck, ocular adnexa, and lungs. Several small studies have reported that observation alone may be appropriate in selected patients with ocular adnexal MALToma.

Use of the International Prognostic Index—which takes into account age, Ann Arbor stage, lactate dehydrogenase (LDH) level, the number of extranodal sites, and performance status—has better characterized low-, intermediate-, and high-risk groups. The 5-year survival rates for those groups are as follows:

Patients with early-stage MALToma may be curable with chemotherapy. The risks and benefits of surgical or radiation therapy for MALTomas should be considered before the decision is made to proceed with such treatment.

Glickman MS, Pamer EG. Cell-Mediated Defense against Infection. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, Pa: Elsevier; 2010. 129-50.

Bufo P. Academic lesson; 1999. The MALTomas.

Santacroce L. Academic lesson; 1997. Anatomy, physiology and surgical pathophysiology of the MALT.

Zucca E, Bertoni F. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. Blood. 2016 Apr 28. 127 (17):2082-92. [Medline]. [Full Text].

Beagley KW, Elson CO. Cells and cytokines in mucosal immunity and inflammation. Gastroenterol Clin North Am. 1992 Jun. 21(2):347-66. [Medline].

Featherstone C. M cells: portals to the mucosal immune system. Lancet. 1997 Oct 25. 350(9086):1230. [Medline].

Hamzaoui N, Pringault E. Interaction of microorganisms, epithelium, and lymphoid cells of the mucosa-associated lymphoid tissue. Ann N Y Acad Sci. 1998 Nov 17. 859:65-74. [Medline].

Dubois B, Barthélémy C, Durand I, et al. Toward a role of dendritic cells in the germinal center reaction: triggering of B cell proliferation and isotype switching. J Immunol. 1999 Mar 15. 162(6):3428-36. [Medline]. [Full Text].

Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med. 2000 Jul 6. 343(1):37-49. [Medline].

Delves PJ, Roitt IM. The immune system. Second of two parts. N Engl J Med. 2000 Jul 13. 343(2):108-17. [Medline].

Chin YH, Cai JP, Hieselaar T. Lymphocyte migration into mucosal lymphoid tissues: mechanism and modulation. Immunol Res. 1991. 10(3-4):271-8. [Medline].

Keren DF. Intestinal mucosal immune defense mechanisms. Am J Surg Pathol. 1988. 12 suppl 1:100-5. [Medline].

Rosebeck S, Lucas PC, McAllister-Lucas LM. Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment. Future Oncol. 2011 May. 7(5):613-7. [Medline]. [Full Text].

Stolte M, Bayerdörffer E, Morgner A, et al. Helicobacter and gastric MALT lymphoma. Gut. 2002 May. 50 Suppl 3:III19-24. [Medline]. [Full Text].

Pérez de Diego R, Sánchez-Ramón S, López-Collazo E, Martínez-Barricarte R, Cubillos-Zapata C, Ferreira Cerdán A, et al. Genetic errors of the human caspase recruitment domain-B-cell lymphoma 10-mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (CBM) complex: Molecular, immunologic, and clinical heterogeneity. J Allergy Clin Immunol. 2015 Nov. 136 (5):1139-49. [Medline]. [Full Text].

Nocturne G, Virone A, Ng WF, Le Guern V, Hachulla E, Cornec D, et al. Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren’s Syndrome. Arthritis Rheumatol. 2016 Apr. 68 (4):977-85. [Medline].

Cavalli F, Isaacson PG, Gascoyne RD, Zucca E. MALT Lymphomas. Hematology Am Soc Hematol Educ Program. 2001. 241-58. [Medline]. [Full Text].

Fung CY, Grossbard ML, Linggood RM, et al. Mucosa-associated lymphoid tissue lymphoma of the stomach: long term outcome after local treatment. Cancer. 1999 Jan 1. 85(1):9-17. [Medline]. [Full Text].

Chen T, Cen L, Xiao R, Yang JH, Jiang NK, Lu XZ, et al. [Prognostic value of t(11; 18) (q21; q21) for gastric mucosa-associated lymphoid tissue lymphoma]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2012 Apr. 29(2):181-3. [Medline].

Perry C, Herishanu Y, Metzer U, et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol. 2007 Sep. 79(3):205-9. [Medline].

Fischbach W, Schramm S, Goebeler E. Outcome and quality of life favour a conservative treatment of patients with primary gastric lymphoma. Z Gastroenterol. 2011 Apr. 49(4):430-5. [Medline].

Chen Y, Inobe J, Marks R, et al. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature. 1995 Jul 13. 376(6536):177-80. [Medline].

Bachert C, Möller P. [The tonsils as MALT (mucosa-associated lymphoid tissue) of the nasal mucosa] [German]. Laryngorhinootologie. 1990 Oct. 69(10):515-20. [Medline].

Kracke A, Hiller AS, Tschernig T, et al. Larynx-associated lymphoid tissue (LALT) in young children. Anat Rec. 1997 Jul. 248(3):413-20. [Medline].

Lugton I. Mucosa-associated lymphoid tissues as sites for uptake, carriage and excretion of tubercle bacilli and other pathogenic mycobacteria. Immunol Cell Biol. 1999 Aug. 77(4):364-72. [Medline].

Ferreri AJ, Assanelli A, Crocchiolo R, et al. Therapeutic management of ocular adnexal MALT lymphoma. Expert Opin Pharmacother. 2007 Jun. 8(8):1073-83. [Medline].

Wündisch T, Dieckhoff P, Greene B, Thiede C, Wilhelm C, Stolte M, et al. Second Cancers and Residual Disease in Patients Treated for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma by Helicobacter pyloriEradication and Followed for 10 Years. Gastroenterology. 2012 Jun 27. [Medline].

Gong EJ, Ahn JY, Jung HY, Park H, Ko YB, Na HK, et al. Helicobacter pylori Eradication Therapy Is Effective as the Initial Treatment for Patients with H. pylori-Negative and Disseminated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Gut Liver. 2016 Sep 15. 10 (5):706-13. [Medline]. [Full Text].

Cheung DY. Helicobacter pylori Eradication Therapy, the Reasonable First Line Therapy for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Irrespective of Infection Status and Disease Stages. Gut Liver. 2016 Sep 15. 10 (5):659-60. [Medline]. [Full Text].

Choi YJ, Lee DH, Kim JY, Kwon JE, Kim JY, Jo HJ, et al. Low Grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma: Clinicopathological Factors Associated with Helicobacter pylori Eradication and Tumor Regression. Clin Endosc. 2011 Dec. 44(2):101-8. [Medline]. [Full Text].

Amiot A, Lévy M, Copie-Bergman C, Dupuis J, Szablewski V, Le Baleur Y, et al. Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study. Aliment Pharmacol Ther. 2014 Mar. 39(6):619-28. [Medline].

Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013 Feb 10. 31(5):565-72. [Medline].

Raderer M, Kiesewetter B, Ferreri AJ. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J Clin. 2016 Mar-Apr. 66 (2):153-71. [Medline]. [Full Text].

Kiesewetter B, Willenbacher E, Willenbacher W, Egle A, Neumeister P, Voskova D, et al. A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. Blood. 2017 Jan 19. 129 (3):383-385. [Medline].

Hu Q, Zhang Y, Zhang X, Fu K. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori infection: a review of current diagnosis and management. Biomark Res. 2016 Jul 27. 4:15. [Medline]. [Full Text].

Sara J Grethlein, MD Associate Dean for Undergraduate Medical Education, Indiana University School of Medicine

Sara J Grethlein, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Society of Hematology, American Society of Clinical Oncology

Disclosure: Nothing to disclose.

Emmanuel C Besa, MD Professor Emeritus, Department of Medicine, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American Society of Clinical Oncology, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, New York Academy of Sciences

Disclosure: Nothing to disclose.

Troy H Guthrie, Jr, MD Director of Cancer Institute, Baptist Medical Center

Troy H Guthrie, Jr, MD is a member of the following medical societies: American Federation for Medical Research, American Medical Association, American Society of Hematology, Florida Medical Association, Medical Association of Georgia, and Southern Medical Association

Disclosure: Nothing to disclose.

Jose A Perez Jr, MD, MBA, MSEd Residency Director, Internal Medicine Residency Program, Vice Chair of Education, Department of Medicine, Methodist Hospital; Associate Professor of Clinical Medicine, Weill Cornell Medical College

Jose A Perez Jr, MD, MBA, MSEd is a member of the following medical societies: American College of Physician Executives, American College of Physicians, Society of General Internal Medicine, and Society of Hospital Medicine

Disclosure: Nothing to disclose.

Karen Seiter, MD Professor, Department of Internal Medicine, Division of Oncology/Hematology, New York Medical College

Karen Seiter, MD is a member of the following medical societies: American Association for Cancer Research, American College of Physicians, and American Society of Hematology

Disclosure: Novartis Honoraria Speaking and teaching; Novartis Consulting fee Speaking and teaching; Eisai Honoraria Speaking and teaching; Celgene Honoraria Speaking and teaching

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Mucosa-Associated Lymphoid Tissue Lymphomas (MALTomas)

Research & References of Mucosa-Associated Lymphoid Tissue Lymphomas (MALTomas)|A&C Accounting And Tax Services